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Lee1 has raised some questions that we are pleased to address regarding our randomised 28 
controlled trial (RCT) on the effect of n-3 long-chain polyunsaturated fatty acids (LCPUFA) 29 
supplementation, predominantly as docosahexaenoic acid (DHA), in pregnancy on the 30 
cumulative incidence of IgE-mediated allergic disease in the first 3 years of life 2.  As 31 
reported in our paper published in the British Medical Journal (BMJ)3, which focussed on 32 
eczema and food allergy outcomes over the first year of life, compliance with the trial 33 
products were good, with less than 2% of mothers in each group choosing not to take any 34 
capsules. At 28 weeks' gestation, 284/368 (77.2%) of mothers in the n-3 LCPUFA group and 35 
280/338 (79.9%) of mothers in the control group reported that they had missed 0 to 3 36 
capsules per week from a total of 21 capsules3. The cord blood concentrations of total n-3 37 
LCPUFA, DHA and eicosapentaenoic acid in the plasma phospholipids from women in the n-38 
3 LCPUFA group were higher (median 8.8%, 7.5% and 0.54%) compared to the control 39 
group (median 7.2%, 6.2% and 0.27%, P<0.0001 for all comparisons) 3. Hence we do not 40 
consider that lack of compliance contributed to our finding that overall n-3 LCPUFA 41 
supplementation during pregnancy did not significantly reduce IgE-associated allergic 42 
disease in the first three years of life.  43 
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We specifically chose the panel of allergens to be tested at 3 years of age to reflect those 45 
found to be most commonly associated with allergen sensitisation in Australian children. 46 
Another study found that the most common allergens to which children are sensitised at 4 47 
years of age are house dust mite (11.9%), grass pollen (7.8%) and cat (5.8%)4. Dog 48 
sensitisation was only reported in 2.5% of children in this study and was not associated with 49 
the presence of a dog in the household4. In our trial, 62.9% of families in the n-3 LCPUFA 50 
group had a dog as a pet in the first 3 years of life compared to 65.7%% of families in the 51 
control group (P=0.44), hence dog ownership was unlikely to have influenced our  trial 52 
outcomes. 53 
 54 
More infants (96.1%) in the n-3 LCPUFA group were initially breastfed than in the control 55 
group (91.0%)3. As breastfeeding was a post-randomisation variable we did not adjust for this 56 
in statistical analyses, however in exploratory analyses we found no relationship between the 57 
initiation of breastfeeding and atopic eczema or egg sensitisation3. Although the cow’s milk 58 
allergen extract became unavailable from the supplier for an extended period during the 3 59 
year assessments, cow’s milk skin prick testing was performed on 666/706 (94.3%) of infants 60 
at 1 year of age, by which age 99% infants had been introduced to cow’s milk3. We did not 61 
find a difference between the groups for cow’s milk sensitisation at 1 year of age, with 1.7% 62 
infants in the n-3 LCPUFA group having a positive skin prick test compared with 1.0% 63 
infants in the control group (P=0.51)3. This was despite more infants in the control group 64 
(79.8%) consuming cow’s milk protein formula in the first six months of life than the n-3 65 
LCPUFA group (72.0%)3. Collectively these data suggest that the small imbalance between 66 
breastfeeding and formula feeding in the first 6 months of life did not influence the outcomes 67 
of the trial.    68 
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In summary, we thank Lee1 for raising their questions, however we do not believe that any of 70 
the issues raised influenced the allergy outcomes of the children in the trial.   71 
 72 
Debra J Palmer, Thomas Sullivan and Maria Makrides 73 
 74 
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